An anti-scar adhesive core-shell microneedle and its preparation method

By constructing anti-scar adhesive core-shell microneedles and utilizing the hyaluronic acid and Schiff base bond mechanism, effective drug delivery and anchoring in hypertrophic scars were achieved, solving the problem of drug loss and promoting the therapeutic effect of hypertrophic scars.

CN123058992APending Publication Date: 2026-11-10THE FIRST PEOPLES HOSPITAL OF FOSHAN
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611554482.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-09
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

In treating hypertrophic scars, current drug delivery protocols struggle to establish a strong bond between the drug and the lesion tissue during the degradation of the extracellular matrix, leading to premature drug loss and increased risk of systemic side effects.

Method used

The study employs anti-scarring adhesive core-shell microneedles. The microneedle shell is a cross-linked polymer network constructed from polyvinyl alcohol and cross-linking agent TSPBA, while the microneedle core is hyaluronic acid containing tissue-adhesive nanomedicine. The microneedle is linked to type I collagenase via Schiff base bonds, and the drug is locally degraded and anchored by utilizing the local slightly acidic environment and hydrogen peroxide response mechanism.

Benefits of technology

While disrupting the physical barrier of hypertrophic scars, it achieves in-situ retention and effective delivery of drugs, reduces inflammation levels, promotes ferroptosis of myofibroblasts, blocks collagen synthesis, and effectively intervenes in hypertrophic scars.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123058992A_ABST
    Figure CN123058992A_ABST
Patent Text Reader

Abstract

This invention discloses an anti-scar adhesive core-shell microneedle and its preparation method, comprising a microneedle shell, a microneedle core, and an internal tissue-adhesive nanomedicine. The microneedle shell is constructed by reacting polyvinyl alcohol with the reactive oxygen species-responsive crosslinking agent TSPBA. The borate ester bond formed by the reaction of polyvinyl alcohol and TSPBA consumes hydrogen peroxide through oxidative cleavage. The microneedle core is composed of hyaluronic acid, which dissolves to establish a slightly acidic environment. The nanomedicine includes a co-assembled core composed of polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer, quercetin, and ferrous ions, and a type I collagenase modified on the surface by Schiff base bonds. Under the slightly acidic environment, the collagenase detaches and degrades the extracellular matrix, and the core exposes free aldehyde groups that covalently anchor to the lesion tissue. After myofibroblasts take up the core, they release ferrous ions and quercetin, synergistically triggering ferroptosis and inhibiting collagen synthesis. This invention solves the technical defect that damage to the matrix barrier easily leads to premature loss of delivered drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of biomedicine and drug delivery technology, specifically to an anti-scarring adhesive core-shell microneedle and its preparation method. Background Technology

[0002] Hypertrophic scars are a common fibrotic disease following deep dermal injury. Their pathogenesis is primarily driven by the abnormal transdifferentiation of normal fibroblasts into myofibroblasts. Myofibroblasts proliferate excessively within the tissue and secrete excessive extracellular matrix, ultimately leading to dense pathological matrix deposition at the lesion site. Currently, local drug delivery systems are commonly used clinically to intervene in hypertrophic scars, inhibiting abnormal cell activity and alleviating the fibrotic process.

[0003] In conventional percutaneous delivery treatments, microneedles or other carriers are typically used to penetrate the scar surface and deliver drugs with anti-fibrotic or abnormal cell-killing effects directly into the tissue. To improve drug penetration efficiency in hard lesions, current technologies often introduce matrix-degrading components such as collagenase or hyaluronidase into the scar tissue simultaneously with drug delivery. These enzyme preparations aim to hydrolyze excessively deposited extracellular matrix, breaking down the dense physical barrier composed of collagen and other proteins, thereby improving the local tissue matrix microenvironment and promoting drug penetration.

[0004] Recent studies have shown that myofibroblasts in the scar microenvironment exhibit a highly specific iron overload state and are highly sensitive to lipid peroxidation and ferroptosis. Selectively clearing myofibroblasts by inducing ferroptosis has become a promising strategy. However, this strategy faces two obstacles in practical application: First, simply inducing ferroptosis cannot resolve the pre-existing dense pathological extracellular matrix deposition; it still requires the use of matrix-degrading components to break down the physical barrier. Second, when degrading enzymes destroy the dense extracellular matrix, the tissue permeability of the scar increases. The opening of the tissue barrier accelerates the flow of interstitial fluid, allowing conventional small-molecule drugs or nanomedicines lacking tissue anchoring ability to diffuse with body fluids, leaking into surrounding interstitial spaces or entering systemic circulation. Premature loss of local therapeutic drugs not only prevents the maintenance of effective therapeutic concentrations within the lesion but also increases the risk of systemic side effects. Therefore, existing delivery methods struggle to establish a strong binding between the drug and the lesion tissue during extracellular matrix degradation, failing to resolve the technical contradiction between disrupting the tissue physical barrier and maintaining long-term in-situ drug retention. Summary of the Invention

[0005] To address the shortcomings of existing technologies, this invention provides an adhesive core-shell microneedle for treating scarring and its preparation method, which solves the problem in existing technologies where degradation of the extracellular matrix during the treatment of hypertrophic scars easily leads to premature loss of locally delivered drugs.

[0006] To achieve the above objectives, the present invention provides the following technical solution: The first aspect of the present invention provides an anti-scar adhesive core-shell microneedle, comprising a microneedle shell, a microneedle core layer encapsulated within the microneedle shell, and a tissue-adhesive nanomedicine distributed within the microneedle core layer; The microneedle shell is a cross-linked polymer network constructed by reacting polyvinyl alcohol with the reactive oxygen species responsive cross-linking agent TSPBA. The matrix material of the microneedle core is hyaluronic acid. The full name of TSPBA is N1,N3-di-(4-phenylboronic)-N1,N1,N3,N3-tetramethylpropane-1,3-diamine. The phenylboronic acid group in its molecule reacts with the vicinal diol structure on the polyvinyl alcohol chain to form a borate ester bond.

[0007] The tissue-adhesive nanomedicine comprises a co-assembled core and an enzyme molecule modified on the surface of the co-assembled core; the co-assembled core is composed of polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer, quercetin and ferrous ions, and the enzyme molecule is type I collagenase; The amino groups on the surface of type I collagenase condense with the free aldehyde groups on the surface of the co-assembled core, achieving covalent linkage through Schiff base bonds.

[0008] Preferably, polyvinyl alcohol reacts with crosslinking agent TSPBA to form a crosslinked polymer network containing borate ester bonds. The borate ester bonds undergo oxidative cleavage under the action of hydrogen peroxide, causing local degradation of the crosslinked polymer network.

[0009] Preferably, in a dry state, the hyaluronic acid molecular chains in the microneedle core layer are intertwined to form a solid matrix network, and the solid matrix network physically encapsulates tissue-adhesive nanomedicines; after the hyaluronic acid absorbs the interstitial fluid, it dissolves, creating a local slightly acidic environment with a pH of about 6.0 around the microneedles.

[0010] Preferably, the Schiff base bond has acid-base dependent reversible chemical properties; under a locally slightly acidic environment, the Schiff base bond connecting type I collagenase and the co-assembled core shifts in equilibrium towards dissociation, type I collagenase detaches from the surface of the co-assembled core, and the surface of the co-assembled core is re-exposed to free aldehyde groups.

[0011] Preferably, the co-assembled core, which re-exposes free aldehyde groups, undergoes a Schiff base reaction with the amino groups of tissue surface proteins to generate new Schiff base bonds, thereby covalently anchoring the co-assembled core within the tissue.

[0012] A second aspect of the present invention provides a method for preparing the anti-scarring adhesive core-shell microneedles described in the first aspect of the present invention, comprising the following independent stages: Polymer synthesis stage: Polylactic acid and hyperbranched glycidyl ether undergo a condensation reaction and are then oxidized to introduce free aldehyde groups, thereby synthesizing a polylactic acid-hyperbranched glycidyl ether-aldehyde copolymer; Nanomedicine assembly stage: Polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer, quercetin and ferrous ions are co-assembled to obtain a co-assembled core; the co-assembled core is mixed with type I collagenase, and the amino groups on the surface of type I collagenase react with the free aldehyde groups on the surface of the co-assembled core to obtain tissue-adhesive nanomedicine. Core-shell microneedle molding stage: A microneedle shell molding liquid containing polyvinyl alcohol and crosslinking agent TSPBA is prepared to form a hollow microneedle shell on the inner wall of the cavity of the microneedle mold; a hyaluronic acid solution containing tissue-adhesive nanomedicine is filled into the hollow cavity of the microneedle shell, dried to form a microneedle core layer encapsulating tissue-adhesive nanomedicine, and demolded to obtain anti-scar adhesive core-shell microneedles.

[0013] Preferably, in the polymer synthesis stage, polylactic acid and hyperbranched polyglycidyl ether are dissolved together in a mixture of dichloromethane and N,N-dimethylformamide, and N,N'-diisopropylcarbodiimide as a condensing agent and 4-dimethylaminopyridine as a catalyst are added to carry out a condensation reaction; after the condensation reaction is completed, the product is purified and oxidized with sodium periodate to introduce free aldehyde groups.

[0014] Preferably, in the nanomedicine assembly stage, polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer, quercetin, and ferrous chloride are dissolved together in dimethyl sulfoxide to form a nanoprecipitate, which is then injected into deionized water to co-assemble via nanoprecipitation. The co-assembled core is purified using an ultrafiltration centrifuge tube with a molecular weight cutoff of 100 kDa. In the mixture with type I collagenase, the mass ratio of the co-assembled core to type I collagenase is 100:1. After reacting for 1 hour, ultrafiltration centrifugation is performed again using an ultrafiltration centrifuge tube with a molecular weight cutoff of 100 kDa for purification.

[0015] Preferably, in the core-shell microneedle forming stage, a 2% polyvinyl alcohol solution and a 2% crosslinking agent TSPBA solution are prepared and mixed at a volume ratio of 2:1 to prepare a microneedle shell forming liquid; during centrifugation and drying, polyvinyl alcohol and crosslinking agent TSPBA undergo chemical crosslinking by forming borate ester bonds, forming a hollow microneedle shell on the inner wall of the cavity.

[0016] Preferably, during the core-shell microneedle molding stage, the concentration of the hyaluronic acid solution containing the tissue-adhesive nanomedicine is 0.3 g / mL; after filling, centrifugation and drying, a hyaluronic acid backing layer solution is laid on the surface, and demolding is performed after complete drying.

[0017] This invention provides an anti-scarring adhesive core-shell microneedle and its preparation method. It has the following beneficial effects: 1. This invention encapsulates a co-assembled core of type I collagenase modified with Schiff base bonds within a hyaluronic acid matrix network. The local slightly acidic environment generated by the dissolution of hyaluronic acid promotes the dissociation of Schiff base bonds and releases type I collagenase to degrade the extracellular matrix. At the same time, the free aldehyde groups re-exposed by the co-assembled core covalently cross-link with the amino groups of proteins on the tissue surface. This achieves the effect of anchoring tissue-adhesive nanomedicines in situ at the lesion while destroying the physical barrier of proliferative scars, thus preventing drug loss with body fluids.

[0018] 2. This invention constructs a cross-linked polymer network for the microneedle shell using polyvinyl alcohol and cross-linking agent TSPBA. The cross-linked polymer network provides mechanical support for the microneedle shell to penetrate dense hypertrophic scar tissue. Furthermore, the borate ester bonds formed by the reaction of polyvinyl alcohol and cross-linking agent TSPBA undergo oxidative cleavage under the action of hydrogen peroxide to consume the hydrogen peroxide in the lesion. This achieves the effect of reducing tissue inflammation level and protecting the internal nanomedicine from damage by reactive oxygen species while ensuring the physical penetration ability of the microneedles.

[0019] 3. This invention promotes the endocytosis and uptake of myofibroblasts by co-assembling free aldehyde groups exposed on the core surface to biochemically adhere to the membrane proteins on the surface of myofibroblasts. It also utilizes the ferrous ions released by the nanomedicine during intracellular dissociation to catalyze the Fenton reaction of hydrogen peroxide, thereby initiating a lipid peroxidation chain reaction. Combined with the released quercetin, it exerts an anti-fibrotic effect and inhibits collagen synthesis and metabolism. This achieves the effect of intervening in hypertrophic scars by inducing ferroptosis in myofibroblasts and blocking collagen synthesis mechanisms. Attached Figure Description

[0020] Figure 1 This is a quantitative analysis diagram of residual drugs in the in vitro polylysine plate simulated adhesion experiment of the present invention; Figure 2 This is a graph illustrating the ability of the nanomedicine of the present invention to induce ferroptosis in myofibroblasts in vitro. Detailed Implementation

[0021] The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0022] An anti-scar adhesive core-shell microneedle includes a microneedle shell, a microneedle core layer encapsulated within the microneedle shell, and a tissue-adhesive nanomedicine distributed within the microneedle core layer. The microneedle shell is a cross-linked polymer network constructed by reacting polyvinyl alcohol with the cross-linking agent TSPBA. The reaction of polyvinyl alcohol with the cross-linking agent TSPBA generates borate ester bonds. The cross-linked polymer network constitutes the external physical morphology of the anti-scar adhesive core-shell microneedle, providing mechanical support for the anti-scar adhesive core-shell microneedle to penetrate the dense tissue of hypertrophic scars. The matrix material of the microneedle core layer is hyaluronic acid, which has dissolving properties when in contact with interstitial fluid. The tissue-adhesive nanomedicine includes a co-assembled core and enzyme molecules modified on the surface of the co-assembled core. The co-assembled core is composed of an aldehyde-modified amphiphilic block copolymer, quercetin, and ferrous ions. Specifically, the amphiphilic block copolymer is a polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer. The enzyme molecule is type I collagenase. The amino groups on the surface of type I collagenase condense with the free aldehyde groups on the surface of the co-assembled core, and are covalently linked through Schiff base bonds.

[0023] The overall workflow for anti-scar adhesive core-shell microneedles after insertion into hypertrophic scar tissue is performed according to the following steps: S1, the microneedle shell responds to the microenvironment and consumes reactive oxygen species. After the anti-scarring adhesive core-shell microneedles penetrate into the scar tissue, the borate ester bonds in the microneedle shell undergo oxidative breakage under the action of hydrogen peroxide in the tissue microenvironment. The oxidative breakage process consumes local hydrogen peroxide, reduces the inflammation level of the scar tissue, and protects the tissue-adhesive nanomedicine from oxidative damage before release.

[0024] S2, the microneedle core layer dissolves and regulates the local microenvironment's pH. Hyaluronic acid in the microneedle core layer absorbs interstitial fluid and dissolves, releasing tissue-adhesive nanomedicines into the interstitial space. Simultaneously, the dissolution of hyaluronic acid lowers the local tissue microenvironment's pH to approximately 6.0, establishing a slightly acidic environment.

[0025] S3, the nanomedicine initiates a cascade reaction of matrix degradation and tissue adhesion. In a slightly acidic environment with a pH of approximately 6.0, the Schiff base bond equilibrium connecting type I collagenase and the co-assembly core shifts towards dissociation. Type I collagenase detaches from the surface of the tissue-adhesive nanomedicine, degrading the dense pathological extracellular matrix within the scar lesion and increasing the permeability of the interstitial space. The breaking of the Schiff base bond re-exposes the free aldehyde groups on the surface of the co-assembly core. The exposed free aldehyde groups then react with amino groups on the surface proteins of the scar tissue through a Schiff base reaction, generating a new covalent cross-linked network. This covalent cross-linking establishes a physicochemical anchoring between the tissue-adhesive nanomedicine and the lesion tissue, preventing leakage of the tissue-adhesive nanomedicine when the body fluid flow rate increases due to extracellular matrix degradation.

[0026] S4, Nanomedicine-induced ferroptosis in myofibroblasts. Myofibroblasts internalize tissue-adhesive nanomedicines retained in situ at the lesion site. These nanomedicines dissociate within the myofibroblasts, releasing free ferrous ions and quercetin. The ferrous ions catalyze the Fenton reaction of hydrogen peroxide within the myofibroblasts, generating highly reactive hydroxyl radicals that trigger lipid peroxidation in the myofibroblasts, initiating ferroptosis in the target cells. The released quercetin inhibits collagen synthesis and metabolism within the myofibroblasts, synergistically blocking the continued development of hypertrophic scars in conjunction with the ferroptosis mechanism.

[0027] The external polymer matrix of the anti-scar adhesive core-shell microneedles comprises two parts: a microneedle shell and a microneedle core. The microneedle shell is constructed using polyvinyl alcohol (PVA) and the crosslinking agent TSPBA. PVA provides the polymer backbone, and the reaction between PVA and TSPBA generates borate ester bonds, forming a three-dimensional crosslinked polymer network through chemical crosslinking. This crosslinked polymer network provides the microneedle shell with the mechanical support to penetrate dense hypertrophic scar tissue. The microneedle core is composed of hyaluronic acid, filling the hollow cavity inside the microneedle shell. Hyaluronic acid is located at the center of the anti-scar adhesive core-shell microneedles. In a dry state, the hyaluronic acid molecular chains entangle to form a solid matrix network, within which tissue-adhesive nanomedicines are physically encapsulated.

[0028] After the anti-scar adhesive core-shell microneedles are inserted into hypertrophic scar tissue, the microenvironment response mechanism of the polymer matrix outside the microneedles specifically includes the following steps: In S101, under the action of hydrogen peroxide, the borate ester bonds formed by the reaction of polyvinyl alcohol and the crosslinking agent TSPBA undergo oxidative cleavage, leading to local degradation of the crosslinked polymer network. This oxidation process consumes hydrogen peroxide at the lesion site, reducing the level of oxidative stress and the degree of inflammatory response in the local tissue microenvironment.

[0029] S102, the microneedle shell also forms an antioxidant physical barrier, blocking residual hydrogen peroxide from entering the microneedle core layer and preventing tissue-adhesive nanomedicines from being destroyed by reactive oxygen species before they can exert their therapeutic effects.

[0030] In S201, the hyaluronic acid within the microneedle core layer absorbs the interstitial fluid of the scar tissue and undergoes physical dissolution. As the cross-linked polymer network of the microneedle shell degrades and the interstitial fluid permeates, the inner microneedle core layer directly contacts the tissue fluid. The hyaluronic acid dissolves upon contact with water, causing the solid matrix network to disintegrate, releasing the tissue-adhesive nanomedicine encapsulated within the hyaluronic acid into the interstitial spaces of the hypertrophic scar tissue.

[0031] S202, the physical dissolution process of hyaluronic acid alters the pH of the local microenvironment surrounding the microneedles. After dissolution, hyaluronic acid establishes a locally slightly acidic environment with a pH of approximately 6.0 around the microneedles, providing triggering conditions for the subsequent reversible dissociation of Schiff base bonds.

[0032] Tissue-adhesive nanomedicines are distributed within a hyaluronic acid solid matrix network of microneedle cores. The tissue-adhesive nanomedicines consist of a co-assembled core and type I collagenase modified on the surface of the co-assembled core. The co-assembled core is formed by the self-assembly of polylactic acid-hyperbranched glycidyl ether-aldehyde copolymer, quercetin, and ferrous ions via nanoprecipitation. The polylactic acid-hyperbranched glycidyl ether-aldehyde copolymer is an amphiphilic block copolymer. Polylactic acid segments constitute the hydrophobic center of the co-assembled core, while hyperbranched glycidyl ether segments constitute the hydrophilic shell. Free aldehyde groups are distributed on the surface of the hydrophilic shell. Quercetin and ferrous ions are encapsulated within the co-assembled core. The amino groups on the surface of the type I collagenase undergo a Schiff base reaction with the free aldehyde groups distributed on the hydrophilic shell, generating reversible Schiff base bonds, thus achieving covalent conjugation modification of the type I collagenase on the surface of the co-assembled core.

[0033] The synergistic mechanism of tissue-adhesive nanomedicines in the microenvironment of hypertrophic scars specifically includes the following steps: S301, the Schiff base bond exhibits acid-base dependent reversible chemical properties. In the locally slightly acidic environment formed by the dissolution of hyaluronic acid, the Schiff base bond connecting type I collagenase and the co-assembled core shifts towards dissociation, causing type I collagenase to detach from the surface of the co-assembled core and revert to its catalytically active free state.

[0034] S302 involves the desquamation of dense extracellular matrix in hypertrophic scar lesions by detached type I collagenases. Type I collagenases recognize and hydrolyze pathologically deposited collagen networks, disrupting the physical barrier of hypertrophic scars, expanding interstitial spaces, and improving the efficiency of tissue-adhesive nanomedicines penetrating deeper into the lesion.

[0035] In S303, the free aldehyde groups on the surface of the co-assembled core covalently cross-link with the amino groups on the surface of hypertrophic scar tissue. Extracellular matrix degradation leads to increased interstitial fluid flow. The co-assembled core, exposing the free aldehyde groups, undergoes a Schiff base reaction with the amino groups of proteins on the surface of the lesion, generating new Schiff base bonds. The co-assembled core is anchored in situ at the lesion, preventing tissue-adhesive nanomedicines from being lost with tissue fluid.

[0036] S401, the free aldehyde groups exposed on the surface of the co-assembled core undergo biochemical adhesion with the membrane proteins on the surface of myofibroblasts. The aldehyde-mediated cell membrane adhesion promotes the endocytosis of myofibroblasts and anchors the co-assembled core in situ at the lesion site. After the nanomedicine enters the cell, it dissociates and releases quercetin and ferrous ions into the cytoplasm.

[0037] S402, ferrous ions catalyze the Fenton reaction of hydrogen peroxide within myofibroblasts. The Fenton reaction generates highly reactive hydroxyl radicals. These hydroxyl radicals attack lipid molecules in the myofibroblast cell membrane, initiating a chain reaction of lipid peroxidation, leading to the accumulation of lipid peroxides within the cell and triggering ferroptosis in the myofibroblasts. The chemical equation for the Fenton reaction is as follows:

[0038] In the formula, Represents ferrous ions. Represents hydrogen peroxide. Represents iron ions. Represents hydroxyl radicals, It represents hydroxide ions.

[0039] S403 releases quercetin, which exerts anti-fibrotic effects and inhibits collagen synthesis in myofibroblasts, synergistically blocking the continued development of hypertrophic scars in conjunction with ferroptosis induction.

[0040] The preparation method of anti-scar adhesive core-shell microneedles includes three independent main stages: polymer synthesis, nanomedicine assembly, and core-shell microneedle molding. The specific preparation process of anti-scar adhesive core-shell microneedles is carried out according to the following steps: M1, polymer synthesis stage.

[0041] In M101, polylactic acid (PLA) and hyperbranched glycidyl ether (HGE) are dissolved together in a mixture of dichloromethane and N,N-dimethylformamide. A condensing agent and a catalyst are added to the mixture, causing PLA and HGE to undergo a condensation reaction. The condensing agent used is N,N'-diisopropylcarbodiimide, and the catalyst is 4-dimethylaminopyridine. After the condensation reaction, the product is purified and then oxidized with sodium periodate to introduce free aldehyde groups, generating an amphiphilic block copolymer with free aldehyde groups, namely, PLA-HGE-Hyperbranched Glycidyl Ether-Aldehyde Copolymer.

[0042] M2, the nanomedicine assembly stage.

[0043] M201 involves dissolving polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer, quercetin, and ferrous chloride in dimethyl sulfoxide to form a nanoprecipitate. This nanoprecipitate is then rapidly injected into deionized water. Through nanoprecipitation, the amphiphilic block copolymer co-assembles in deionized water, encapsulating quercetin and ferrous ions within the co-assembled core. The mixture containing the co-assembled core is then purified by centrifugation using an ultrafiltration centrifuge tube with a molecular weight cutoff of 100 kDa to obtain the co-assembled core.

[0044] In M202, the co-assembled core and type I collagenase were mixed in deionized water at a mass ratio of 100:1. After reacting for 1 hour, the amino groups on the surface of the type I collagenase reacted with the free aldehyde groups on the surface of the co-assembled core through a Schiff base reaction. After the reaction was completed, the mixture was purified again by ultrafiltration centrifugation using an ultrafiltration centrifuge tube with a molecular weight cutoff of 100 kDa to prepare tissue-adhesive nanomedicines.

[0045] M3, the core-shell microneedle forming stage.

[0046] M301 involves preparing a 2% polyvinyl alcohol (PVA) solution and a 2% TSPBA crosslinking agent solution. The PVA solution and TSPBA solution are mixed at a preferred volume ratio of 2:1 to prepare a microneedle shell forming liquid. This microneedle shell forming liquid is injected into the cavity of a polydimethylsiloxane (PDMS) microneedle mold. The PDMS microneedle mold is then centrifuged and dried. During the drying process, the PVA and TSPBA undergo chemical crosslinking through the formation of borate ester bonds, forming a hollow microneedle shell on the inner wall of the mold cavity.

[0047] M302 involves dispersing tissue-adhesive nanomedicines in a hyaluronic acid solution, preferably at a concentration of 0.3 g / mL. The hyaluronic acid solution containing the tissue-adhesive nanomedicines is then filled into the hollow cavity inside a microneedle shell. Centrifugation and drying processes are performed to entangle the hyaluronic acid molecular chains, forming a solid matrix network, thus obtaining a microneedle core layer encapsulating the tissue-adhesive nanomedicines.

[0048] M303 involves depositing a hyaluronic acid backing solution onto the surface of a polydimethylsiloxane microneedle mold. After centrifugation and complete drying, the formed core-shell microneedles are demolded from the polydimethylsiloxane microneedle mold to obtain complete, anti-scarring, adhesive core-shell microneedles.

[0049] The specific experimental implementation examples and technical efficacy verification of the anti-scarring adhesive core-shell microneedles were carried out in the following independent phases: E1, in vitro tissue adhesion performance testing stage.

[0050] E101, Preparation of in vitro experimental plates with a poly-L-lysine coating. The poly-L-lysine coating provides an amino-rich, simulated physical surface for simulating the amino enrichment state within hypertrophic scar lesions in an in vitro environment.

[0051] E102, establish a parallel experimental control group. In this embodiment, bFeQ refers to a nanomedicine with aldehyde-adhesive properties formed by co-assembling quercetin and ferrous ions onto a polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer; bFeQ@C refers to the intact nanomedicine after type I collagenase is conjugated to the surface of bFeQ via Schiff base bonds; FeQ is the control group for non-adhesive nanomedicine. Nanomedicines of equal concentration from the above three different groups were prepared and added to the well plates of a poly-L-lysine-coated plate for co-incubation. The incubation time was set to 1 hour.

[0052] After incubation, the E103 plate was thoroughly washed to remove any free nanomedicines that had not undergone covalent bonding on the surface of the plate.

[0053] E104, see appendix Figure 1 The absorbance of the eluent (or desorption solution) for each well after washing was measured. Based on the absorbance, the amount of quercetin residue remaining on the poly-L-lysine coated plate after washing was calculated. The analytical data showed that... Figure 1 Under the experimental conditions of the illustrated embodiment, the drug residue levels measured in the control group of nanomedicines with aldehyde-based adhesion and the experimental group of tissue-adhesive nanomedicines containing type I collagenase were approximately seven times higher than those in the control group without adhesion. Experimental data confirmed that the free aldehyde groups on the surface of the polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer react with the amino groups on the simulated surface via a Schiff base reaction, forming covalent crosslinks. The test results also simultaneously indicated that the surface conjugation modification with type I collagenase did not reduce the overall physicochemical adhesion properties of the nanomedicine, providing a basis for the drug's resistance to body fluid erosion during matrix degradation.

[0054] E2, the in vitro induced ferroptosis assay stage for myofibroblasts.

[0055] E201 was used to culture myofibroblasts in the logarithmic growth phase in vitro. Four intervention variables were established: a free quercetin control group, a non-adhesive nanomedicine control group, an aldehyde-adhesive nanomedicine control group, and a complete tissue-adhesive nanomedicine experimental group. The cultured myofibroblasts were then co-incubated with the four drug groups at predetermined concentration gradients.

[0056] E202, see appendix Figure 2 , attached Figure 2 Figure A shows the cell viability data of myofibroblasts after different drug interventions, with appended... Figure 2 Figure B in the middle section shows the relative levels of lipid peroxide accumulation inside myofibroblasts after drug intervention.

[0057] E203, combined with appendix Figure 2Figure A shows that the three nanomedicine groups containing ferrous ions and quercetin exhibited increasing cytotoxicity with increasing drug concentration, and their cell viability inhibition effect was stronger than that of the free quercetin control group. The hydroxyl radicals generated by the nanomedicines within the cells led to the accumulation of lipid peroxides inside myofibroblasts, verifying that the nanomedicines triggered ferroptosis in myofibroblasts.

[0058] E204, in conjunction with appendix Figure 2 Figure B shows the extraction of lipid peroxide accumulation data for inter-group comparison. The lipid peroxide accumulation levels induced by the nanomedicine with aldehyde group adhesion and the experimental group with intact tissue adhesion were higher than those induced by the non-adhesive nanomedicine control group. Quantitative data confirm that free aldehyde group-mediated cell membrane adhesion enhances the uptake efficiency of nanomedicines by myofibroblasts, thereby increasing the accumulation level of intracellular lipid peroxides.

[0059] The specific detection procedures for CCK-8 assays of cell viability and lipid peroxide fluorescent probes were performed in accordance with the instructions of the standard detection kits. The extraction of absorbance values ​​from solutions and related routine physicochemical detection methods are well-known techniques in this field and will not be elaborated upon here.

[0060] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. An anti-scarring adhesive core-shell microneedle, characterized in that, It includes a microneedle shell, a microneedle core layer encapsulated within the microneedle shell, and tissue-adhesive nanomedicines distributed within the microneedle core layer; The microneedle shell is a cross-linked polymer network constructed by reacting polyvinyl alcohol with the reactive oxygen species responsive cross-linking agent TSPBA, and the matrix material of the microneedle core is hyaluronic acid; The tissue-adhesive nanomedicine comprises a co-assembled core and an enzyme molecule modified on the surface of the co-assembled core; the co-assembled core is composed of polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer, quercetin and ferrous ions, and the enzyme molecule is type I collagenase; The amino groups on the surface of the type I collagenase undergo condensation with the free aldehyde groups on the surface of the co-assembled core, achieving covalent linkage through Schiff base bonds.

2. The anti-scarring adhesive core-shell microneedle according to claim 1, characterized in that, The cross-linked polymer network contains borate ester bonds formed by the reaction of polyvinyl alcohol and cross-linking agent TSPBA. These borate ester bonds undergo oxidative cleavage under the action of hydrogen peroxide, causing localized degradation of the cross-linked polymer network.

3. The anti-scarring adhesive core-shell microneedle according to claim 1, characterized in that, In a dry state, the molecular chains of hyaluronic acid in the microneedle core layer entangle with each other to form a solid matrix network, and the tissue-adhesive nanomedicine is physically encapsulated inside the solid matrix network; after the hyaluronic acid absorbs the interstitial fluid, it dissolves, creating a local slightly acidic environment with a pH of 6.0 around the microneedles.

4. The anti-scarring adhesive core-shell microneedle according to claim 3, characterized in that, The Schiff base bond has acid-base dependent reversible chemical properties; under the local slightly acidic environment, the Schiff base bond connecting the type I collagenase and the co-assembled core shifts in equilibrium towards dissociation, the type I collagenase detaches from the surface of the co-assembled core, and the surface of the co-assembled core is re-exposed to the free aldehyde group.

5. The anti-scarring adhesive core-shell microneedle according to claim 4, characterized in that, The co-assembled core, with its free aldehyde groups re-exposed, undergoes a Schiff base reaction with the amino groups of proteins on the tissue surface to generate new Schiff base bonds, thereby covalently anchoring the co-assembled core within the tissue.

6. A method for preparing an anti-scarring adhesive core-shell microneedle according to claim 1, characterized in that, Includes the following stages: Polymer synthesis stage: Polylactic acid and hyperbranched polyglycidyl ether undergo a condensation reaction and are then oxidized to introduce the free aldehyde group, thereby synthesizing the polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer; Nanomedicine assembly stage: The polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer, quercetin and ferrous ions are co-assembled to obtain the co-assembled core; The co-assembled core is mixed with the type I collagenase, and the amino groups on the surface of the type I collagenase react with the free aldehyde groups on the surface of the co-assembled core to obtain the tissue-adhesive nanomedicine; Core-shell microneedle molding stage: A microneedle shell molding liquid containing polyvinyl alcohol and crosslinking agent TSPBA is prepared to form a hollow microneedle shell on the inner wall of the cavity of the microneedle mold; a hyaluronic acid solution containing the tissue-adhesive nanomedicine is filled into the hollow cavity of the microneedle shell, dried to form the microneedle core layer encapsulating the tissue-adhesive nanomedicine, and demolded to obtain the anti-scar adhesive core-shell microneedle.

7. The preparation method according to claim 6, characterized in that, In the polymer synthesis stage, the polylactic acid and the hyperbranched polyglycidyl ether are dissolved together in a mixture of dichloromethane and N,N-dimethylformamide. N,N'-diisopropylcarbodiimide as a condensing agent and 4-dimethylaminopyridine as a catalyst are added to carry out the condensation reaction. After the condensation reaction is completed, the product is purified and oxidized with sodium periodate to introduce the free aldehyde group.

8. The preparation method according to claim 6, characterized in that, In the nanomedicine assembly stage, the polylactic acid-hyperbranched polyglycidyl ether-aldehyde copolymer, quercetin, and ferrous chloride are dissolved together in dimethyl sulfoxide to form a nanoprecipitate. This precipitate is then injected into deionized water to undergo co-assembly via nanoprecipitation. The co-assembled core is purified using an ultrafiltration centrifuge tube with a molecular weight cutoff of 100 kDa. In the mixture with type I collagenase, the mass ratio of the co-assembled core to the type I collagenase is 100:

1. After reacting for 1 hour, the mixture is again purified by ultrafiltration centrifugation using an ultrafiltration centrifuge tube with a molecular weight cutoff of 100 kDa.

9. The preparation method according to claim 6, characterized in that, In the core-shell microneedle forming stage, a 2% polyvinyl alcohol solution and a 2% crosslinking agent TSPBA solution are prepared and mixed at a volume ratio of 2:1 to prepare the microneedle shell forming liquid; during the centrifugation and drying processes, the polyvinyl alcohol and the crosslinking agent TSPBA undergo chemical crosslinking to form the hollow microneedle shell on the inner wall of the cavity.

10. The preparation method according to claim 6, characterized in that, In the core-shell microneedle molding stage, the concentration of the hyaluronic acid solution in which the tissue-adhesive nanomedicine is dispersed is 0.3 g / mL; after filling, centrifugation and drying, a hyaluronic acid backing layer solution is laid on the surface, and demolding is performed after complete drying.